<DOC>
	<DOC>NCT02820558</DOC>
	<brief_summary>This study evaluates the delivery of substance P via the celiac artery in the treatment of recent onset type 1 diabetes.</brief_summary>
	<brief_title>Neuropeptide Therapy of Recent Onset Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<criteria>Recent onset T1D (CDA 2013 guidelines: See link in links section Age 1018 years Disease Duration 330 months Fasting CPeptide (measured at screening) greater than or equal to 33 pmol/L Post honeymoon phase based on the following criteria: History of HbA1c values and insulin requirements from diagnosis indicating a honeymoon period followed by increased insulin requirements which at time of recruitment are &gt; 0.50 units/Kg together with an HbA1c value &gt; 7.2 %; Patients with diabetes duration &gt; 3 months who never experienced a honeymoon period as reflected by consistent HbA1c values &gt; 7.2 % from the time of diagnosis and at the time of recruitment are using an insulin dose &gt; 0.50 units/Kg. The presence of one or more of the TRPV1 alleles similar to those found in patients currently enrolled in the TRPV1North American European Study. Stimulated CPeptide (measured at mixed meal tolerance at Stage A and Stage B of sP trial) â‰¥ 200 pmol/L and less than or equal to 1500 pmol/L. Patients with known comorbidities, including ACEinhibitor treated hypertension as well as chromosomal abnormalities, involving one or more organ systems. Type 2 Diabetes Mellitus Patients with a known radiographic contrast allergy Pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Neuropeptide</keyword>
	<keyword>Therapy</keyword>
	<keyword>Onset</keyword>
</DOC>